CytomX Therapeutics Inc CTMX:NASDAQ

Last Price$1.84NASDAQ Previous Close - Last Trade as of 4:00PM ET 7/01/22

Today's Change+0.01(0.55%)
Bid (Size)$1.93 (1)
Ask (Size)$1.86 (27)
Day Low / High$1.83 - 1.91
Volume471.4 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 07/01/2022


CytomX Therapeutics Inc ( NASDAQ )

Price: $1.84
Change: +0.01 (0.55%)
Volume: 471.4 K
4:00PM ET 7/01/2022

MediciNova Inc ( NASDAQ )

Price: $2.47
Change: -0.06 (2.37%)
Volume: 17.7 K
4:00PM ET 7/01/2022

Actinium Pharmaceuticals Inc ( NYSE MKT LLC )

Price: $4.96
Change: +0.15 (3.12%)
Volume: 134.4 K
8:00PM ET 7/01/2022

Otonomy Inc ( NASDAQ )

Price: $2.07
Change: -0.01 (0.48%)
Volume: 95.5 K
4:00PM ET 7/01/2022

RVL Pharmaceuticals PLC ( NASDAQ )

Price: $1.41
Change: +0.05 (3.68%)
Volume: 34.3 K
4:00PM ET 7/01/2022

Read more news Recent News

CytomX Therapeutics Shares Edge Higher After BMO Capital Starts Coverage
12:57PM ET 6/24/2022 MT Newswires

CytomX Therapeutics (CTMX) shares gained more than 1% in Friday afternoon trading after BMO Capital started coverage of the company with an outperform...

BMO Capital Starts CytomX Therapeutics at Outperform With $9 Price Target
4:55AM ET 6/24/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...

Piper Sandler Adjusts Price Target on CytomX Therapeutics to $10 From $16, Reiterates Overweight Rating
5:25AM ET 5/31/2022 MT Newswires

CytomX Therapeutics (CTMX) has an average rating of buy and price targets ranging from $6 to $16, according to analysts polled by Capital IQ. (MT Newswires...

CytomX Therapeutics Doses First Patient in Early Trial of CX-904 to Treat Advanced Solid Tumors
9:37AM ET 5/26/2022 MT Newswires

CytomX Therapeutics (CTMX) said Thursday it has dosed the first patient in a phase 1 dose-escalation study of CX-904, a drug candidate to fight cancer...

Company Profile

Business DescriptionCytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA. View company web site for more details
Address151 Oyster Point Boulevard
South San Francisco, California 94080-1913
Number of Employees137
Recent SEC Filing06/21/20228-K
Chairman, President & Chief Executive OfficerSean A. McCarthy
Chief Financial Officer & Senior Vice PresidentCarlos E. Campoy
Senior Vice President & Head-ResearchMarcia P. Belvin
Chief Medical Officer & Senior Vice PresidentAlison L. Hannah

Company Highlights

Price Open$1.83
Previous Close$1.83
52 Week Range$1.51 - 7.53
Market Capitalization$120.3 M
Shares Outstanding65.4 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/04/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.41
Beta vs. S&P 500N/A
Revenue$59.5 M
Net Profit Margin-129.97%
Return on Equity-91.89%

Analyst Ratings as of 06/22/2022

Consensus RecommendationConsensus Icon
Powered by Factset